title: PGS consensus statement on management of hepatitis B virus infection--2003.
authors.forename: Z
authors.initials: Z
authors.lastname: Abbas
authors.forename: W
authors.initials: W
authors.lastname: Jafri
authors.forename: S H A
authors.initials: SH
authors.lastname: Shah
authors.forename: N
authors.initials: N
authors.lastname: Khokhar
authors.forename: S J
authors.initials: SJ
authors.lastname: Zuberi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D006509:Hepatitis B / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy* / Q000635:transmission; D006511:Hepatitis B Antigens / Q000097:blood; D017325:Hepatitis B Vaccines; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D010154:Pakistan / Q000453:epidemiology; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine